Karyopharm Therapeutics Inc.
Szimbólum: KPTI
NASDAQ
1.37
USDMai piaci árfolyam
-0.9064
P/E arány
-0.0160
PEG-arány
157.64M
MRK Cap
- 0.00%
DIV hozam
Karyopharm Therapeutics Inc. (KPTI) Pénzügyi kimutatások
Mérleg
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 897.57 | 192.1 | 278 | 228.6 | |||||||||||||
balance-sheet.row.short-term-investments | 636.07 | 139.2 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.net-receivables | 132.37 | 27 | 47.1 | 22.5 | |||||||||||||
balance-sheet.row.inventory | 13.65 | 3 | 4.2 | 4.1 | |||||||||||||
balance-sheet.row.other-current-assets | 226.73 | 11.8 | 19.8 | 2.9 | |||||||||||||
balance-sheet.row.total-current-assets | 1069.53 | 233.9 | 326.8 | 258.1 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 23.05 | 4.9 | 7.4 | 1.6 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-investments | 1.7 | 0.3 | 0.6 | 0.6 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.other-non-current-assets | 39.74 | 1.3 | 23.4 | 44.9 | |||||||||||||
balance-sheet.row.total-non-current-assets | 64.5 | 6.5 | 31.4 | 47.2 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.account-payables | 15.4 | 3.1 | 2.8 | 1.6 | |||||||||||||
balance-sheet.row.short-term-debt | 12.56 | 3.3 | 2.9 | 2.3 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 686.92 | 170.9 | 170.1 | 169.3 | |||||||||||||
Deferred Revenue Non Current | 530.39 | 132.5 | 132.7 | 133 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -395.13 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 172.27 | 63 | 60.3 | 0.7 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 1358.64 | 307.2 | 374.8 | 385 | |||||||||||||
balance-sheet.row.other-liabilities | -123.63 | 0 | -65.9 | -73.7 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 25.52 | 2.8 | 9 | 11.3 | |||||||||||||
balance-sheet.row.total-liab | 1487.05 | 376.6 | 374.8 | 385 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.05 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.retained-earnings | -5721 | -1487 | -1343.9 | -1178.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.1 | -0.2 | -0.6 | 0.2 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5370.03 | 1351 | 1327.9 | 1098.8 | |||||||||||||
balance-sheet.row.total-stockholders-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1134.03 | - | - | - | |||||||||||||
Total Investments | 636.37 | 139.5 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.total-debt | 696.11 | 177 | 173 | 169.3 | |||||||||||||
balance-sheet.row.net-debt | 434.6 | 124.1 | 37.8 | -21.2 |
Cash Flow kimutatás
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.6 | 0.8 | |||||||||||||
cash-flows.row.deferred-income-tax | 5.92 | -1.1 | 0 | 1.5 | |||||||||||||
cash-flows.row.stock-based-compensation | 21.71 | 21.7 | 35.4 | 29.8 | |||||||||||||
cash-flows.row.change-in-working-capital | 31.41 | 31.4 | -20 | -23.2 | |||||||||||||
cash-flows.row.account-receivables | 20.12 | 20.1 | -5.1 | -9.6 | |||||||||||||
cash-flows.row.inventory | 1.18 | 1.2 | -0.1 | -1.5 | |||||||||||||
cash-flows.row.account-payables | 0.35 | 0.3 | 1.2 | -2.8 | |||||||||||||
cash-flows.row.other-working-capital | -0.7 | 9.8 | -16 | -9.3 | |||||||||||||
cash-flows.row.other-non-cash-items | -9.19 | -2.2 | -0.3 | 8.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -92.72 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 104.3 | 5.5 | |||||||||||||
cash-flows.row.purchases-of-investments | -159.15 | -159.2 | -226 | -45.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 167.09 | 167.1 | 121.9 | 192.8 | |||||||||||||
cash-flows.row.other-investing-activites | -18.9 | 0 | -104.3 | -5.5 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 7.94 | 7.9 | -104.3 | 141.8 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -60 | |||||||||||||
cash-flows.row.common-stock-issued | 1.12 | 1.1 | 189.8 | 9.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 1.12 | 1.1 | 4 | 123.7 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 39.69 | 1.1 | 193.7 | 73.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.03 | 0 | -0.5 | 0 | |||||||||||||
cash-flows.row.net-change-in-cash | -83.61 | -83.4 | -60.6 | 108.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 264.86 | 52.9 | 136.9 | 197.4 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 348.48 | 136.3 | 197.4 | 89.1 | |||||||||||||
cash-flows.row.operating-cash-flow | -92.72 | -92.7 | -149.6 | -107.1 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.free-cash-flow | -92.72 | -92.7 | -149.7 | -112.8 |
Eredménykimutatás sor
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 146.03 | 146 | 157.1 | 209.8 | |||||||||||||
income-statement-row.row.cost-of-revenue | 5.02 | 5.5 | 5.2 | 3.4 | |||||||||||||
income-statement-row.row.gross-profit | 141.01 | 140.6 | 151.9 | 206.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 138.67 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 131.88 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.operating-expenses | 270.55 | 270.1 | 294.1 | 304.7 | |||||||||||||
income-statement-row.row.cost-and-expenses | 275.57 | 275.6 | 299.3 | 308.1 | |||||||||||||
income-statement-row.row.interest-income | 10.94 | 10.9 | 2.4 | 0.6 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.total-operating-expenses | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.58 | 0.5 | 2.3 | 0.5 | |||||||||||||
income-statement-row.row.ebitda-caps | -121.1 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -129.54 | -129.5 | -142.2 | -98.3 | |||||||||||||
income-statement-row.row.income-before-tax | -142.78 | -142.8 | -164.9 | -123.8 | |||||||||||||
income-statement-row.row.income-tax-expense | 0.32 | 0.3 | 0.4 | 0.3 | |||||||||||||
income-statement-row.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 |
Gyakran ismételt kérdés
Mi a Karyopharm Therapeutics Inc. (KPTI) az összes eszköz?
Karyopharm Therapeutics Inc. (KPTI) az összes eszköz 240438000.000.
Mekkora a vállalkozás éves bevétele?
Az éves bevétel 69756000.000.
Mennyi a cég haszonkulcsa?
A cég haszonkulcsa 0.966.
Mennyi a vállalat szabad cash flow-ja?
A szabad pénzáramlás -0.808.
Mi a vállalati nettó haszonkulcs?
A nettó haszonkulcs -0.980.
Mennyi a vállalat teljes bevétele?
A teljes bevétel -0.887.
Mi a Karyopharm Therapeutics Inc. (KPTI) nettó profit (nettó nyereség)?
A nettó nyereség (nettó bevétel) -143099000.000.
Mennyi a cég teljes adóssága?
Az összes adósság 177016000.000.
Mi a működési költségek száma?
A működési költségek 270101000.000.
Mennyi a cég készpénzállománya?
A vállalati pénzeszközök 52891000.000.